Patient value: Perspectives from the patient advocacy community

In this paper, a group of patient advocates explore the varying definitions of patient value and make positive recommendations for working together to strengthen the patient voice in this area. The authors call on framework developers, the patient advocacy and research communities, the healthcare industry and decision-makers to undertake specific actions to ensure patient value […] [...]

read more

European Society of Medical Oncology (ESMO) highlights from the IKCC

The International Kidney Cancer Coalition (IKCC) had a booth at the European Society of Medical Oncology (ESMO) 2017 conference in Madrid last week. Please follow the link below to read the kidney cancer highlights from the conference. Read the kidney cancer highlights from ESMO on the IKCC website [...]

read more

NHS England spotlight on specialised services – a new report

A new report from NHS England, Spotlight on specialised services, provides an insight into the specialised services that are currently delivered and the services to be rolled out over the coming years. The following are of relevance to cancer: Upgrading radiotherapy equipment – £130 million had been committed to ‘the biggest upgrade in NHS cancer treatment in […] [...]

read more

Cancer patients struggle to understand clinical trials

The results of a survey involving 1090 adult cancer patients suggesting cancer patients struggle to understand what is involved in a clinical trial were presented at the European Society of Medical Oncology (ESMO) 2017 conference in Madrid last week. In the survey, more than half of the patients did not understand the concept of randomisation […] [...]

read more

Kidney cancer highlights from the European Society of Medical Oncology

The following is an interview with Dr Toni K. Choueiri, medical oncologist at the Dana-Farber Cancer Institute, Boston, US, about the kidney cancer highlights from the European Society of Medical Oncology (ESMO) 2017 conference in Madrid, Spain this week. During this interview he talks about the updated CABOSUN (cabozantinib versus sunitinib) clinical trial results, updated CheckMate-214 (nivolumab plus […] [...]

read more

New combination treatment shows promise in kidney cancer

Results from a phase I clinical trial with a combination of X4P-001-IO plus axitinib in patients with clear cell renal cell carcinoma (ccRCC) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain this week. The early phase results demonstrated encouraging disease control rates and durable responses with the new […] [...]

read more
Showing 1 to 6 of 232 results
  TOP